You just read:

DelMar Pharmaceuticals Announces Successful Completion of End-of-Phase 2 Meeting with FDA on VAL-083 for the Treatment of Refractory Glioblastoma Multiforme

News provided by

DelMar Pharmaceuticals, Inc.

May 25, 2016, 08:00 ET